Selfotel, formerly known as CGS-19755 and CPDD 0027, is a competitive NMDA antagonist. Selfotel directly competes with glutamate for binding to the receptor. Initial studies showed it to have anticonvulsant, anxiolytic, analgesic and neuroprotective effects, and it was originally researched for the treatment of stroke, but subsequent animal and human studies showed phencyclidine-like effects, as well as limited efficacy and evidence for possible neurotoxicity under some conditions, and so clinical development was ultimately discontinued. References: Dziuganowska ZA, Slepokura K, Volle JN, Virieux D, Pirat JL, Kafarski P. Structural Analogues of Selfotel. J Org Chem. 2016 Jun 17;81(12):4947-54. doi: 10.1021/acs.joc.6b00220. Epub 2016 Jun 1. PubMed PMID: 27187758.

纯度：≥98%

CAS：110347-85-8